Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer

European Organization for the Research and Treatment of Cancer (EORTC)- Investigational Drug Branch for Breast Cancer (IDBBC), R Paridaens, L Dirix, C Lohrisch, L Beex, M Nooij, D Cameron, L Biganzoli, T Cufer, L Duchateau, A Hamilton, J P Lobelle, M Piccart

Research output: Contribution to journalArticlepeer-review

Abstract

Women with hormone-responsive metastatic breast cancer (MBC) may respond to or have stable disease with a number of hormone therapies. We explored the efficacy and safety of the steroidal aromatase inactivator exemestane as first-line hormonal therapy in MBC in postmenopausal women.
Original languageEnglish
Pages (from-to)1391-8
Number of pages8
JournalAnnals of Oncology
Volume14
Issue number9
Publication statusPublished - Sep 2003

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Androstadienes
  • Antineoplastic Agents, Hormonal
  • Breast Neoplasms
  • Female
  • Humans
  • Middle Aged
  • Postmenopause
  • Tamoxifen
  • Treatment Outcome

Fingerprint

Dive into the research topics of 'Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer'. Together they form a unique fingerprint.

Cite this